Respiratory System Deposition with a Novel Aerosol Delivery System in Spontaneously Breathing Healthy Adults

References

1. 1.↵
   1. Fischl MA,
   2. Pitchenik A,
   3. Gardner LB

   . An index predicting relapse and need for hospitalization in patients with acute bronchial asthma. N Engl J Med 1981;305(14):783-789.

   OpenUrlCrossRefPubMedWeb of Science
2. 2.↵
   1. Mohammed S,
   2. Goodacre S

   . Intravenous and nebulised magnesium sulphate for acute asthma: systematc review and meta-analysis. Emerg Med J 2007;24(12):832-830.

   OpenUrl
3. 3.↵
   1. Cheuk DK,
   2. Chau TC,
   3. Lee SL

   . A meta-analysis on intravenous magnesium sulphate for treating acute asthma. Arch Dis Child 2005;90(1):74-77.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Schuh S,
   2. Zemek R,
   3. Plint A,
   4. Black KJL,
   5. Freedman S,
   6. Porter R,
   7. et al

   . Practice patterns in asthma discharge pharmacotherapy in pediatric emergency departments: a pediatric emergency research Canada study. Acad Emerg Med 2012;19(5):1019-1026.

   OpenUrl
5. 5.↵
   1. Okayama H,
   2. Aikawa T,
   3. Okayama M,
   4. Saski H,
   5. Mue S,
   6. Takishima T

   . Bronchodilating effect of intravenous magnesium sulfate in bronchial asthma. JAMA 1987;257(8):1076-1078.

   OpenUrlCrossRefPubMedWeb of Science
6. 6.↵
   1. Blitz M,
   2. Blitz S,
   3. Beasley R,
   4. Diner BM,
   5. Hughes R,
   6. Knopp JA

   . Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database Syst Rev 2005;(4):CD003898.
7. 7.↵
   1. Aggarwal P,
   2. Sharad S,
   3. Handa R,
   4. Dwiwedi SN,
   5. Irshad M

   . Comparison of nebulised magnesium sulfate and salbutamol combined with salbutamol alone in the treatment of acute bronchial asthma: a randomised study. Emerg Med J 2006;23(5):358-362.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Hughes R,
   2. Goldkorn A,
   3. Masoli M,
   4. Weatherall M,
   5. Burgess C,
   6. Beasley R

   . Use of isotonic nebulised magnesium sulfpate as an adjuvant to salbutamol in the treatment of severe asthma: radomised placebo controlled trial. Lancet 2003;361(9375):2114-2117.

   OpenUrlCrossRefPubMedWeb of Science
9. 9.↵
   1. Dodd M,
   2. Abbott J,
   3. Maddison J,
   4. Moorcroft AJ,
   5. Webb AK

   . Effect of tonicity of nebulized colistin on chest tightness and pulmonary function in adults with cystic fibrosis. Thorax 1997;52(7):656-658.

   OpenUrlAbstract
10. 10.↵
    1. Coates AL,
    2. Leung K,
    3. Vecellio L,
    4. Schuh S

    . Testing of nebulizers for delivery of magnesium sulfate to pediatric asthma patients in the emergency department. Respir Care 2011;56(3):314-318.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Coates AL,
    2. Green M,
    3. Leung K,
    4. Louca E,
    5. Tservistas M,
    6. Chan J,
    7. et al

    . The challenges of quantitative measurement of lung deposition using ^99mTc-DTPA from delivery systems with very different delivery times. J Aerosol Med 2007;20(3):320-330.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Coates AL,
    2. MacNeish CF,
    3. Dinh L,
    4. Rollin T,
    5. Gagnon S,
    6. Ho SL,
    7. Lands LC

    . Accounting for radioactivity before and after nebulization of tobramycin to insure accuracy of quantification of lung deposition. J Aerosol Med 2000;13(3):169-178.

    OpenUrlPubMedWeb of Science
13. 13.↵
    1. Macey DJ,
    2. Marshall R

    . Absolute quantitation of radiotracer uptake in the lungs using a gamma camera. J Nucl Med 1982;23(8):731-735.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    1. Brown JS,
    2. Zeman KL,
    3. Bennett WD

    . Regional deposition of coarse particles and ventilation distribution in healthy subjects and patients with cystic fibrosis. J Aerosol Med 2001;14(4):443-454.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Coates AL,
    2. MacNeish CF,
    3. Lands LC,
    4. Smountas A,
    5. Meisner D,
    6. Kelemen S,
    7. Vadas EB

    . Factors influencing the rate of drug output during the course of wet nebulization. J Aerosol Med 1998;11(2):101-111.

    OpenUrl
16. 16.↵
    1. Coates AL,
    2. Green M,
    3. Leung K,
    4. Chan J,
    5. Ribeiro N,
    6. Ratjen F,
    7. Charron M

    . A comparison of amount and speed of deposition between the Pari LC Star jet nebulizer and an investigational eFlow nebulizer. J Aerosol Med Pulmon Drug Del 2011;24(3):157-163.

    OpenUrl
17. 17.↵
    1. Coates AL,
    2. Green M,
    3. Leung K,
    4. Chan J,
    5. Ribeiro N,
    6. Louca E,
    7. et al

    . Rapid pulmonary delivery of inhaled tobramycin for pseudomonas infection in cystic fibrosis: a pilot project. Pediatr Pulmonol 2008;43(8):753-759.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Coates AL,
    2. Denk O,
    3. Leung K,
    4. Ribeiro N,
    5. Chan J,
    6. Green M,
    7. et al

    . Higher tobramycin concentration and vibrating mesh technology can shorten antibiotic treatment time in cystic fibrosis. Pediatr Pulmonol 2011;46(4):401-408.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Chua HL,
    2. Collis GG,
    3. Newbury AM,
    4. Chan K,
    5. Bower GD,
    6. Sly PD,
    7. LeSouëf PN

    . The influence of age on aerosol deposition in children with cystic fibrosis. Eur Respir J 1994;7(12):2185-2191.

    OpenUrlAbstract/FREE Full Text
20. 20.↵
    1. Ilowite JS,
    2. Gorvoy JD,
    3. Smaldone GC

    . Quantitative deposition of aerosolized gentamycin in cystic fibrosis. Am Rev Respir Dis 1987;136(6):1445-1449.

    OpenUrlPubMedWeb of Science
21. 21.↵
    1. Kwong WTJ,
    2. Ho SL,
    3. Coates AL

    . Comparison of nebulized particle size distribution with Malvern laser diffraction analyzer versus Andersen cascade impactor and low-flow Marple personal cascade impactor. J Aerosol Med 2000;13(4):303-314.

    OpenUrlPubMedWeb of Science
22. 22.↵
    1. Coates AL,
    2. MacNeish CF,
    3. Meisner D,
    4. Kelemen S,
    5. Thibert R,
    6. MacDonald J,
    7. Vadas EB

    . The choice of jet nebulizer, nebulizing flow and the addition of ventolin respiratory solution affects tobramycin aerosols used in cystic fibrosis. Chest 1997;111(5):1206-1212.

    OpenUrlCrossRefPubMedWeb of Science
23. 23.
    1. Newman SP,
    2. Pellow PG,
    3. Clay MM,
    4. Clarke SW

    . Evaluation of jet nebulisers for use with gentamycin solution. Thorax 1985;40(9):671-676.

    OpenUrlAbstract/FREE Full Text
24. 24.↵
    1. Clay MM,
    2. Pavia D,
    3. Newman SP,
    4. Clarke SW

    . Factors influencing the size distribution of aerosols from jet nebulisers. Thorax 1983;38(10):755-759.

    OpenUrlAbstract/FREE Full Text
25. 25.↵
    1. Taulbee DB,
    2. Yu CP

    . A theory of aerosol deposition in the human respiratory tract. J Appl Physiol 1975;38(1):77-85.

    OpenUrlAbstract/FREE Full Text
26. 26.↵
    1. Brain JD,
    2. Valberg PA

    . Deposition of aerosol in the respiratory tract —state of the Art. Am Rev Respir Dis 1979;120(6):1325-1373.

    OpenUrlPubMedWeb of Science
27. 27.↵
    1. Bates DV,
    2. Macklem PT,
    3. Christie RV

    1. Bates DV,
    2. Macklem PT,
    3. Christie RV

    . The normal lung: physiology and methods of study. In: Bates DV, Macklem PT, Christie RV, editors. Respiratory function in disease, 2nd edition. Philadelphia: WB Saunders; 1971:10-95.
28. 28.↵
    1. Chernick V,
    2. Boat TE,
    3. Wilmott RW,
    4. Bush A

    1. Chernick V,
    2. West JB

    . The functional basis of respiratory disease. In: Chernick V, Boat TE, Wilmott RW, Bush A, editors. Kendig's disorders of the respiratory tract in children, 7th edition. Philadelphia: Saunders/Elsevier; 2006:29-64.
29. 29.↵
    1. Coates AL,
    2. Allen PD,
    3. MacNeish CF,
    4. Ho SL,
    5. Lands LC

    . Effect of size and disease on expected deposition of drugs given by jet nebulization to children with cystic fibrosis. Chest 2001;119(4):1123-1130.

    OpenUrlCrossRefPubMedWeb of Science
30. 30.↵
    1. Geller DE,
    2. Pitlick WH,
    3. Nardella PA,
    4. Tracewell WG,
    5. Ramsey BW

    . Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 2002;122(1):219-226.

    OpenUrlCrossRefPubMedWeb of Science
31. 31.↵
    1. Jannsens HM,
    2. Krijgsman A,
    3. Verbraak TF,
    4. Hop WC,
    5. de Jongste JC,
    6. Tiddens HA

    . Determining factors of aerosol deposition for four pMDI-spacer combinations in an infant upper airway model. J Aerosol Med 2004;17(1):51-61.

    OpenUrlCrossRefPubMedWeb of Science
32. 32.↵
    1. Coates AL,
    2. Tipples GA,
    3. Leung K,
    4. Gray M,
    5. Louca E

    ; WHO Product Development Group for Measles Aerosol Vaccine. How many infective particles are necessary for successful mass measles immunization by aerosol? Vaccine 2006;14(10):1578-1585.

    OpenUrl
33. 33.↵
    1. Schuepp KG,
    2. Jauernig J,
    3. Janssens HM,
    4. Tiddens HA,
    5. Straub DA,
    6. Stangl R,
    7. et al

    . In vitro determination of optimal particle size for nebulized aerosol delivery to infants. J Aerosol Med 2005;18(2):225-235.

    OpenUrlPubMed
34. 34.↵
    1. Tal A,
    2. Golan H,
    3. Grauer N,
    4. Aviram M,
    5. Albin D,
    6. Quastel MR

    . Deposition pattern of radiolabeled salbutamol inhaled from a meter-dose inhaler by means of a spacer with mask in young children with airway obstruction. J Pediatr 1996;128(4):479-484.

    OpenUrlCrossRefPubMedWeb of Science